Innovation Theaters

November 11-13


TECENTRIQ: FIRST FDA-APPROVED ADJUVANT CANCER IMMUNOTHERAPY IN NSCLC
Martin Dietrich, MD, PhD
Thursday, November 11 at 11:25 AM Pacific
Presented by:


Please join us to learn about an FDA-approved first line monotherapy option in advanced NSCLC
Chaitali Nangia, MD
Thursday, November 11 at 2:10 PM Pacific
Presented by:


EGFR Exon20 insertion+ mNSCLC and a new FDA-approved therapy
Martin Dietrich, MD, PhD
Friday, November 12 at 1:05 PM Pacific
Presented by:


Exploring a Treatment Option for Patients With Previously Treated Metastatic Small Cell Lung Cancer (SCLC)
Mahendra Gupta, MD, MBA
Saturday, November 13 at 10:55 AM Pacific
Presented by:

 

This Innovation Theater is available during Personalized Therapies in Thoracic Oncology. The opinions and recommendations expressed do not necessarily reflect the views of the Personalized Therapies in Thoracic Oncology, Imedex, HMP Global or NACCME. This program is not intended or eligible for continuing education (CME/CE) credits and does not meet guidelines governing CME/CE. By viewing this Innovation Theater, you opt-in to share/receive information with/from industry sponsors. If you wish to opt-out, email: optouts@thoraciccancermeeting.com